On August 14, 2026, at the preliminary round of the 10th “Red Boat Cup” Jiaxing Global Entrepreneurship Competition – Life & Health Track, Dr. Weijie Chen, Chairman of Lishan Biotech, presented the “Live Biologic Drug LBP Project for Intestinal Microbiota”. Standing out among 20 cutting‑edge innovation projects for its outstanding originality and industrialization potential, the project was awarded the First Prize and successfully qualified for the Grand Final. Hosted by Zhejiang Tsinghua Yangtze River Delta Research Institute, the competition adopts the theme “Grow with You, Innovate for the Future”. It focuses on four strategic sectors: life and health, intelligent equipment, new energy and new materials, as well as embodied intelligence, and solicits high‑caliber entrepreneurial projects world...

On July 8, 2026, Shanghai Lishan Biotech Co., Ltd. officially received the Intellectual Property Compliance Management System Certification Certificate issued by Zhongzhi (Beijing) Certification Co., Ltd. This certification marks a further upgrade in the systematic management of the Company’s intellectual property work. It represents a key achievement of Lishan Biotech in continuously improving its innovation management system and strengthening its capability to protect core technologies, laying a more solid foundation for AI‑empowered living biologic drug R&D and future industrial development. Intellectual property constitutes a vital component of the core competitiveness of innovative enterprises, as well as critical support for translating scientific research achievements into industrial applications. The acquisition of this certification bears...

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity Article Source：Evogene Official Website https://evogene.com/newsroom/press-release/evogene-announces-successful-completion-of-phase-1-clinical-study-of-bmc128-a-rationally-designed-live-bacterial-product-in-combination-with-nivolumab-by-its-subsidiary-biomica/ REHOVOT, Israel, June 2, 2026 – Evogene Ltd. (“Evogene”) (Nasdaq/TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced s...

April 24, 2026 – Dr. Weijie Chen, Chairman of Lishan Biotech, has added another honor to his name. At the 2025 Pudong New Area “Pearl Cup” Entrepreneurship Competition, Dr. Chen and his team won the “Most Promising Overseas Returnee Entrepreneurship Team Award” for their project, the “World-Class Live Biotherapeutic Product (LBP) Platform for Gut Microbiome.” The competition was hosted by Pudong Venture Capital Group and guided by the Pudong New Area Talent Work Bureau. It aimed to attract overseas and domestic tech talent entrepreneurship projects through a model of “competition-based evaluation and investment linkage.” Focusing on three leading industries—integrated circuits, biomedicine, and artificial intelligence—the competition drew numerous projects from home and abroa...

Innovation Drives the Future——Though the Journey is Long, Perseverance Leads to Success Recently, Shanghai Lishan Biotech Co., Ltd. has received exciting news—it has officially been recognized as a National High-Tech Enterprise and has been awarded the "High-Tech Enterprise Certificate" jointly issued by the Shanghai Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Office of the State Administration of Taxation. This recognition marks that Lishan Biotech has met the national standards for high-tech enterprises in areas such as innovative drug development, technological innovation, and achievement commercialization, serving as a strong endorsement of the company's sustained innovation capabilities and scientific research strength.   AI-Empowered: The Innovation Engine f...

At the beginning of the Year of the Horse, on the afternoon of February 26th, the "New Overseas Chinese Innovation and Entrepreneurship in Shanghai" activity, organized by the Shanghai Federation of Returned Overseas Chinese to visit overseas Chinese enterprises and facilitate practical work, entered Zhangjiang Pharma Valley and held a thematic seminar at Lishan Biotech. A delegation comprising Qi Quansheng, Party Secretary and Chairman of the Shanghai Federation of Returned Overseas Chinese; Guo Qing, Vice Chairman of the Municipal Federation and concurrently Party Secretary and Chairman of the Pudong New Area Federation; and Cheng Dong, Chairman of the Zhangjiang Science City Federation, among others, visited the company. Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, and Shang Jing, Executive D...

BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results   Rehovot, Israel and Shanghai, China – February 4, 2026 – Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biotech Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene’s subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiom...